FI941424A - Fluoratut 17beta-substituoidut 4-atsa-5alfa-androstan-3-onijohdannaiset - Google Patents

Fluoratut 17beta-substituoidut 4-atsa-5alfa-androstan-3-onijohdannaiset Download PDF

Info

Publication number
FI941424A
FI941424A FI941424A FI941424A FI941424A FI 941424 A FI941424 A FI 941424A FI 941424 A FI941424 A FI 941424A FI 941424 A FI941424 A FI 941424A FI 941424 A FI941424 A FI 941424A
Authority
FI
Finland
Prior art keywords
hydrogen
fluorine
alkyl
5alpha
17beta
Prior art date
Application number
FI941424A
Other languages
English (en)
Swedish (sv)
Other versions
FI941424A0 (fi
FI113778B (fi
Inventor
Achille Panzeri
Marcella Nesi
Salle Enrico Di
Original Assignee
Erba Carlo Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Erba Carlo Spa filed Critical Erba Carlo Spa
Publication of FI941424A0 publication Critical patent/FI941424A0/fi
Publication of FI941424A publication Critical patent/FI941424A/fi
Application granted granted Critical
Publication of FI113778B publication Critical patent/FI113778B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
    • C07J73/005—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by nitrogen as hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Lubricants (AREA)
  • Glass Compositions (AREA)
  • Percussion Or Vibration Massage (AREA)
FI941424A 1992-07-31 1994-03-28 Menetelmä farmaseuttisesti käyttökelpoisten fluorattujen 17beta-substituoitujen 4-atsa-5alfa-androstan-3-oni-johdannaisten valmistamiseksi FI113778B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9216284 1992-07-31
GB929216284A GB9216284D0 (en) 1992-07-31 1992-07-31 Fluorinated 17beta-substituted 4-aza-5alpha-androstane-3-one derivatives
EP9302037 1993-07-29
PCT/EP1993/002037 WO1994003475A1 (en) 1992-07-31 1993-07-29 FLUORINATED 17β-SUBSTITUTED 4-AZA-5α-ANDROSTAN-3-ONE DERIVATIVES

Publications (3)

Publication Number Publication Date
FI941424A0 FI941424A0 (fi) 1994-03-28
FI941424A true FI941424A (fi) 1994-05-27
FI113778B FI113778B (fi) 2004-06-15

Family

ID=10719598

Family Applications (1)

Application Number Title Priority Date Filing Date
FI941424A FI113778B (fi) 1992-07-31 1994-03-28 Menetelmä farmaseuttisesti käyttökelpoisten fluorattujen 17beta-substituoitujen 4-atsa-5alfa-androstan-3-oni-johdannaisten valmistamiseksi

Country Status (29)

Country Link
US (1) US5407939A (fi)
EP (1) EP0607400B1 (fi)
JP (1) JP3325025B2 (fi)
KR (1) KR100311547B1 (fi)
CN (1) CN1041096C (fi)
AT (1) ATE159951T1 (fi)
AU (1) AU660562B2 (fi)
CA (1) CA2120343A1 (fi)
CZ (1) CZ286240B6 (fi)
DE (1) DE69315050T2 (fi)
DK (1) DK0607400T3 (fi)
ES (1) ES2110620T3 (fi)
FI (1) FI113778B (fi)
GB (1) GB9216284D0 (fi)
GR (1) GR3025546T3 (fi)
HK (1) HK1011693A1 (fi)
HU (2) HUT67043A (fi)
IL (1) IL106520A (fi)
MX (1) MX9304579A (fi)
MY (1) MY109633A (fi)
NO (1) NO305401B1 (fi)
NZ (1) NZ254787A (fi)
PH (1) PH29938A (fi)
PL (1) PL178591B1 (fi)
RU (1) RU2125061C1 (fi)
TW (1) TW286319B (fi)
UA (1) UA41291C2 (fi)
WO (1) WO1994003475A1 (fi)
ZA (1) ZA935481B (fi)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2151239A1 (en) * 1992-12-18 1994-07-07 Glenn J. Gormley Method of treatment of chronic prostatitis with 17b-n- monosubstituted-carbamoyl-4-aza-5a-androst-1-en-3-ones
DK0705272T3 (da) * 1993-06-24 2002-05-27 Richter Gedeon Vegyeszet Særlig fremgangsmåde til fremstilling af 17beta-substituerede 4-azaandrostanderivater
TW369521B (en) * 1993-09-17 1999-09-11 Smithkline Beecham Corp Androstenone derivative
WO1995011254A1 (en) * 1993-10-21 1995-04-27 Merck & Co., Inc. 16-substituted-4-aza-androstane 5-alpha-reductase isozyme 1 inhibitors
GB9415178D0 (en) * 1994-07-28 1994-09-21 Erba Carlo Spa 4-azasteroids with side-chain fluoroketones
US5541322A (en) * 1994-10-14 1996-07-30 Glaxo Wellcome Inc. Synthesis of 6-azaandrostenones
US5543417A (en) * 1994-10-21 1996-08-06 Merck & Co., Inc. Combination method of treating acne using 4-AZA-5α-cholestan-ones and 4-AZA-5α-androstan-ones as selective 5α-reductase inhibitors with anti-bacterial, keratolytic, or anti-inflammatory agents
US5595996A (en) * 1994-10-25 1997-01-21 Merck & Co., Inc. 7-substituted 4-aza cholanic acid derivatives and their use
IT1275594B1 (it) * 1995-07-21 1997-08-06 Pharmacia S P A Ora Pharmacia Epimeri del (22rs)-n-(1,1,1-trifluoro-2-fenilprop-2-il)-3-osso -4-aza-5alfa-androst-1-ene-17beta-carbossammide
GB9518858D0 (en) * 1995-09-14 1995-11-15 Pharmacia Spa Phenylsubstituted 4-azasteroid fluoroderivatives
GB9727522D0 (en) * 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Process for preparing carboxamido-4-azasteroids
US6645974B2 (en) * 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof
PL372920A1 (en) * 2002-03-13 2005-08-08 Merck & Co,Inc. Fluorinated 4-azasteroid derivatives as androgen receptor modulators
CN100528168C (zh) * 2003-06-30 2009-08-19 麦克公司 作为雄激素受体调节剂的17-乙酰氨基-4-氮杂甾类衍生物
CA2530182A1 (en) 2003-06-30 2005-01-20 Merck & Co., Inc. 17-acetamido-4-azasteroid derivatives as androgen receptor modulators
JP2007521293A (ja) * 2003-06-30 2007-08-02 メルク　エンド　カムパニー　インコーポレーテッド アンドロゲン受容体モジュレータとしての１７−アセトアミド−４−アザステロイド誘導体
WO2005004807A2 (en) * 2003-06-30 2005-01-20 Merck & Co., Inc. 17-acetamido-4-azasteroid derivatives as androgen receptor modulators
US7446110B2 (en) * 2003-09-10 2008-11-04 Merck & Co., Inc. 17-Heterocyclic-4-azasteroid derivatives as androgen receptor modulators
CA2537663A1 (en) 2003-09-10 2005-03-24 Merck & Co., Inc. 17-heterocyclic-4-azasteroid derivatives as androgen receptor modulators
US20080125399A1 (en) * 2004-04-08 2008-05-29 Jiabing Wang 17 Beta-Acetamide-4-Azasteroids As Androgen Receptor Modulators
CN102282133A (zh) * 2008-10-28 2011-12-14 生物马林药物股份有限公司 十氢-1h-茚并喹啉酮和十氢-3h-环戊并菲啶酮cyp17抑制剂

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ211145A (en) * 1984-02-27 1988-10-28 Merck & Co Inc 4-aza-5-alpha-androst-1-en-3-ones and pharmaceutical compositions
GB8505862D0 (en) * 1985-03-07 1985-04-11 Erba Farmitalia Steroidic 5alpha-reductase inhibitors
GB9002922D0 (en) * 1990-02-09 1990-04-04 Erba Carlo Spa 17 beta-substituted-4-aza-5 alpha-androstan-3-one derivatives and process for their preparation
IE76452B1 (en) * 1990-10-29 1997-10-22 Sankyo Co Azasteroid compounds for the treatment of prostatic hypertrophy their preparation and use
US5304562A (en) * 1991-10-09 1994-04-19 Ciba-Geigy Corporation 17β-substituted Aza-androstane derivatives
AUPP930799A0 (en) * 1999-03-18 1999-04-15 University Of Sydney, The Optical planar waveguide device and method of its fabrication

Also Published As

Publication number Publication date
IL106520A0 (en) 1993-11-15
RU2125061C1 (ru) 1999-01-20
ES2110620T3 (es) 1998-02-16
UA41291C2 (uk) 2001-09-17
HUT67043A (en) 1995-01-30
DE69315050T2 (de) 1998-03-05
DK0607400T3 (da) 1998-01-26
FI941424A0 (fi) 1994-03-28
HU9400914D0 (en) 1994-06-28
AU660562B2 (en) 1995-06-29
JPH06511497A (ja) 1994-12-22
ATE159951T1 (de) 1997-11-15
US5407939A (en) 1995-04-18
GB9216284D0 (en) 1992-09-16
NO941080L (no) 1994-05-18
TW286319B (fi) 1996-09-21
ZA935481B (en) 1994-05-16
DE69315050D1 (de) 1997-12-11
NZ254787A (en) 1995-11-27
MY109633A (en) 1997-03-31
NO941080D0 (no) 1994-03-24
JP3325025B2 (ja) 2002-09-17
HU211238A9 (en) 1995-11-28
CZ286240B6 (cs) 2000-02-16
CN1041096C (zh) 1998-12-09
HK1011693A1 (en) 1999-07-16
GR3025546T3 (en) 1998-03-31
NO305401B1 (no) 1999-05-25
CZ153893A3 (en) 1994-02-16
CA2120343A1 (en) 1994-02-17
MX9304579A (es) 1994-02-28
PH29938A (en) 1996-09-16
PL178591B1 (pl) 2000-05-31
CN1085224A (zh) 1994-04-13
EP0607400A1 (en) 1994-07-27
FI113778B (fi) 2004-06-15
WO1994003475A1 (en) 1994-02-17
KR100311547B1 (ko) 2002-06-20
AU4704893A (en) 1994-03-03
EP0607400B1 (en) 1997-11-05
IL106520A (en) 1997-11-20

Similar Documents

Publication Publication Date Title
FI941424A (fi) Fluoratut 17beta-substituoidut 4-atsa-5alfa-androstan-3-onijohdannaiset
AU537414B2 (en) Pyroglutamic acid derivatives
AU596389B2 (en) 1-arylpyrazoles
DK0551849T3 (da) Arylcycloalkylderivater, deres fremstilling og anvendelse
ES2001106A6 (es) Procedimiento para la obtencion de 1-aril-pirazoles
KR900701717A (ko) 2--1,3-시클로헥산디온제초제 화합물과 이를 이용한 조성물 및 식물억제방법
DE69334206D1 (de) Substituierte hexahydrobenzo(a) phenanthridine
DK0696585T3 (da) Nyt bisoxadiazolidinderivat
AU572668B2 (en) 5-acylamino-1-phenylpyrazoles
ES480873A1 (es) Un procedimiento para la obtencion de triazolidin-3-onas o- tionas.
ES8801670A1 (es) Un procedimiento para preparar nuevos compuestos de 2-oxa pregnano.
ES8801542A1 (es) Procedimiento para preparar compuestos arilsulfonicos.
GB2003866A (en) Thiourea derivatives
ATE148462T1 (de) Isoxazole derivate als lichtschutzmittel
DE69104731D1 (de) 3-(2-chloro-4-trifluoromethyl-phenoxy)-1-azetidinkarboxamide mit antikrampfmachender aktivität.
ES2077697T3 (es) Derivados de 1-fenoxicarbonil-2-pirrolidinona y agentes nootropicos.
MX9706627A (es) Derivado de tiazolidinona opticamente activo.

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: PHARMACIA & UPJOHN S.P.A.

MA Patent expired